Stockreport

Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case [Seeking Alpha]

Nuvation Bio Inc. Class A  (NUVB) 
PDF NUVB reported 204 new patients for Ibtrozi in the latest quarter, supporting a robust revenue trajectory and validating the product's market potential. A conservative [Read more]